Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ADCT
stocks logo

ADCT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
18.33M
+8.4%
-0.290
-0%
19.65M
-14.69%
-0.275
-23.61%
19.95M
+5.9%
-0.275
-45%
Estimates Revision
The market is revising Downward the revenue expectations for ADC Therapeutics SA (ADCT) for FY2025, with the revenue forecasts being adjusted by -2.99% over the past three months. During the same period, the stock price has changed by 0.00%.
Revenue Estimates for FY2025
Revise Downward
down Image
-2.99%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-6.71%
In Past 3 Month
Stock Price
No Change
down Image
0.00%
In Past 3 Month
Wall Street analysts forecast ADCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADCT is 7.33 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast ADCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADCT is 7.33 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.540
sliders
Low
5.00
Averages
7.33
High
10.00
Current: 3.540
sliders
Low
5.00
Averages
7.33
High
10.00
H.C. Wainwright
Robert Burns
Buy
downgrade
$8 -> $7
2025-10-16
Reason
H.C. Wainwright
Robert Burns
Price Target
$8 -> $7
2025-10-16
downgrade
Buy
Reason
H.C. Wainwright analyst Robert Burns lowered the firm's price target on ADC Therapeutics to $7 from $8 and keeps a Buy rating on the shares. The firm reduced the price target after factoring in the private placement financing.
RBC Capital
Gregory Renza
Outperform
downgrade
$8 -> $5
2025-06-21
Reason
RBC Capital
Gregory Renza
Price Target
$8 -> $5
2025-06-21
downgrade
Outperform
Reason
RBC Capital analyst Gregory Renza lowered the firm's price target on ADC Therapeutics to $5 from $8 but keeps an Outperform rating on the shares. The firm says the company's high efficacy for Zynlonta in DLBCL gives it confidence in its likelihood to show clinically meaningful benefits in the 2nd line LOTIS-5 study, unlocking an additional $200M+ U.S. sales opportunity, the analyst tells investors in a research note. RBC adds that ADC shares are undervalued on the balance of a largely de-risked asset with multiple expansion opportunities that can reaccelerate growth.
Guggenheim
Buy
maintain
$7 -> $10
2025-06-13
Reason
Guggenheim
Price Target
$7 -> $10
2025-06-13
maintain
Buy
Reason
Guggenheim raised the firm's price target on ADC Therapeutics to $10 from $7 and keeps a Buy rating on the shares after the company released an update on their Phase 1b LOTIS-7 study of Zynlonta plus glofitamab as part of the EHA embargo lift. ADC also announced a $100M private placement financing intended to support Zynlonta's ongoing clinical programs and commercialization in earlier line DLBCL, as well as a restructuring comprising a 30% reduction in force and closure of UK operations, notes the analyst, who is updating the firm's estimates for all of these events.
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$8
2025-03-31
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$8
2025-03-31
Reiterates
Strong Buy
Reason
Guggenheim
Michael Schmidt
Strong Buy
Maintains
$10 → $7
2025-03-31
Reason
Guggenheim
Michael Schmidt
Price Target
$10 → $7
2025-03-31
Maintains
Strong Buy
Reason
Guggenheim lowered the firm's price target on ADC Therapeutics to $7 from $10 and keeps a Buy rating on the shares. Q4 results were largely consistent with prior disclosures, though Zynlonta sales of $16.4M came in below Street consensus, the analyst tells investors. The firm is updating its model to reflect a slightly more conservative timeline for potential Zynlonta label expansion into second-line Diffuse Large B-Cell Lymphoma as well as Q4 financial results.
Cantor Fitzgerald
Eric Schmidt
Buy
Reiterates
n/a
2025-03-07
Reason
Cantor Fitzgerald
Eric Schmidt
Price Target
n/a
2025-03-07
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for ADC Therapeutics SA (ADCT.N) is -3.15, compared to its 5-year average forward P/E of -3.44. For a more detailed relative valuation and DCF analysis to assess ADC Therapeutics SA 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.44
Current PE
-3.15
Overvalued PE
-0.46
Undervalued PE
-6.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.48
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.44
Undervalued EV/EBITDA
-6.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
14.82
Current PS
0.00
Overvalued PS
48.48
Undervalued PS
-18.84
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

ADCT News & Events

Events Timeline

(ET)
2025-12-03
07:40:00
ADC Therapeutics Updates Zynlonta Clinical Trial Data
select
2025-11-10 (ET)
2025-11-10
07:37:44
ADC Therapeutics announces Q3 adjusted EPS of 19 cents, falling short of consensus estimate of 36 cents.
select
2025-10-13 (ET)
2025-10-13
07:36:26
ADC Therapeutics reports approximately $15.8M in Q3 sales for Zynlonta
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-04Benzinga
PinnedWhat’s Causing ADC Therapeutics' Sharp Decline Today?

  • Market Reaction: ADC Therapeutics SA's stock fell 23.15% to $3.53 following the release of trial results for its cancer drug Zynlonta, despite promising efficacy data from the LOTIS-7 trial.

  • Trial Results: The LOTIS-7 Phase 1b trial showed an overall response rate of 89.8% and a complete response rate of 77.6% among 49 patients with relapsed or refractory diffuse large B-cell lymphoma.

  • Efficacy in Subgroups: The drug demonstrated strong efficacy, with a 100% overall response rate in relapsed patients and an 80% rate in primary refractory patients, while the combination treatment was generally well tolerated.

  • Future Plans: Enrollment in the LOTIS-7 trial is ongoing, with full data expected to be shared at a medical meeting and submitted for publication by the end of 2026.

[object Object]
Preview
9.0
12-03NASDAQ.COM
PinnedADC Therapeutics to Share Progress on LOTIS-7 Clinical Trial

  • Conference Call Announcement: ADC Therapeutics is hosting a conference call today at 8:00 a.m. EST to discuss updates on its LOTIS-7 trial.

  • LOTIS-7 Trial Overview: The LOTIS-7 trial is a Phase 1b study assessing the safety and efficacy of ZYNLONTA in combination with Roche's COLUMVI for patients with relapsed or refractory diffuse large B-cell lymphoma.

  • Promising Results: Preliminary results from the LOTIS-7 trial indicate that the combination of ZYNLONTA and COLUMVI achieved a 93.3% overall response rate and an 86.7% complete response rate among 30 evaluable patients.

  • Stock Performance: ADC Therapeutics' stock closed at $4.60, reflecting an increase of 8.49% on Tuesday.

[object Object]
Preview
2.0
12-04Benzinga
Snowflake, Symbotic, and Other Major Stocks Decline in Thursday's Pre-Market Trading

  • U.S. Stock Futures: U.S. stock futures showed mixed results, with Dow futures up by approximately 0.1% on Thursday morning.

  • Snowflake Inc Performance: Snowflake Inc reported third-quarter revenue of $1.21 billion, surpassing analyst expectations, but its shares fell 8.6% in pre-market trading.

  • Other Stocks Declining: Several other stocks experienced significant declines in pre-market trading, including Net Lease Office Properties down 14.7% and Symbotic Inc down 10.5% following a share offering announcement.

  • Additional Stock Movements: Other notable declines included Capricor Therapeutics down 8.4% after a previous surge, and ADC Therapeutics down 8.1% after reporting trial data.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is ADC Therapeutics SA (ADCT) stock price today?

The current price of ADCT is 3.54 USD — it has decreased -10.38 % in the last trading day.

arrow icon

What is ADC Therapeutics SA (ADCT)'s business?

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

arrow icon

What is the price predicton of ADCT Stock?

Wall Street analysts forecast ADCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADCT is 7.33 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is ADC Therapeutics SA (ADCT)'s revenue for the last quarter?

ADC Therapeutics SA revenue for the last quarter amounts to 16.43M USD, decreased -11.03 % YoY.

arrow icon

What is ADC Therapeutics SA (ADCT)'s earnings per share (EPS) for the last quarter?

ADC Therapeutics SA. EPS for the last quarter amounts to -0.36 USD, decreased -14.29 % YoY.

arrow icon

What changes have occurred in the market's expectations for ADC Therapeutics SA (ADCT)'s fundamentals?

The market is revising Downward the revenue expectations for ADC Therapeutics SA (ADCT) for FY2025, with the revenue forecasts being adjusted by -2.99% over the past three months. During the same period, the stock price has changed by 0.00%.
arrow icon

How many employees does ADC Therapeutics SA (ADCT). have?

ADC Therapeutics SA (ADCT) has 263 emplpoyees as of December 05 2025.

arrow icon

What is ADC Therapeutics SA (ADCT) market cap?

Today ADCT has the market capitalization of 438.52M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free